InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (49 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
49
T+90 hit rate
26%
T+90 mean return
-5.1%
Across 42 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Malik Fady Ibraham, Deputy Chief Executive. Insider active across 2 companies, notably Cytokinetics INC. In total, 107 disclosures have been logged. Split: 0 buy · 49 sells. Total volume traded: €7m. History available since 13 May 2021. The latest transaction was disclosed on 21 April 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations107 total
3,500 sharesCommon StockSEC:0001061983-26-000069:0
3,500 sharesCommon StockSEC:0001061983-26-000069:1
3,500 sharesCommon StockSEC:0001061983-26-000067:0
3,500 sharesCommon StockSEC:0001061983-26-000067:1
3,500 shares@ US$7.800.0003% mcap0.2% of flowCommon StockSEC:0001061983-26-000043:0
3,500 shares@ US$65.690.0025% mcap1.7% of flowCommon StockSEC:0001061983-26-000043:1
2,105 shares@ US$10.600.2% of flowCommon StockSEC:0001061983-25-000025:0
2,105 shares@ US$58.220.9% of flowCommon StockSEC:0001061983-25-000025:1
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001061983-25-000009:0
2,000 shares@ US$60.560.9% of flowCommon StockSEC:0001061983-25-000009:1
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001061983-25-000005:0
2,000 shares@ US$49.280.7% of flowCommon StockSEC:0001061983-25-000005:1
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001127602-25-019021:0
2,000 shares@ US$33.760.5% of flowCommon StockSEC:0001127602-25-019021:1
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001127602-25-015023:0
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001127602-25-013482:0
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001127602-25-012436:0
2,000 shares@ US$38.110.6% of flowCommon StockSEC:0001127602-25-012436:1
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001127602-25-011829:0
2,000 shares@ US$36.180.6% of flowCommon StockSEC:0001127602-25-011829:1
200 shares0Common StockSEC:0001127602-25-010043:0
2,000 shares@ US$10.600.2% of flowCommon StockSEC:0001127602-25-009780:0
39,450 shares0Common StockSEC:0001127602-25-009760:0
4,389 shares@ US$44.381.6% of flowCommon StockSEC:0001127602-25-009711:0
8,228 shares@ US$43.272.9% of flowCommon StockSEC:0001127602-25-008791:0
25 of 107 declarations
About Malik Fady Ibraham
Public sources indicate that Fady I. Malik, M.D., Ph.D., is Executive Vice President, Research & Development at Cytokinetics. The company’s official profile says he has led Research and Development since 2014 and has been with Cytokinetics since its founding in 1998. It also states that he earned a B.S. in bioengineering from the University of California at Berkeley and an M.D./Ph.D. from the University of California at San Francisco, has authored or co-authored more than 60 publications, and serves on the board of Rocket Pharmaceuticals. Sources: https://cytokinetics.com/company/senior-management/team-member/fady-i-malik/
